Acadia pins hopes on pimavanserin after job cuts
This article was originally published in Scrip
Executive Summary
Acadia Pharmaceuticalswill cut its staff and drug development activities as it restructures the business to lower expenses. The plan, which will reduce its workforce by half and refocus development to its late-stage pipeline, will help Acadia extend operations until 2010.